WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive (Biosp... Out-licensing drugs to MNCs is a natural step for Chinese biotechs, but the recent rise in deals is only scratching at the surface of partnership-ready biotechs in the re...
(8/6/2025)

China Biopharma Tracker – July 2025: Funding ... (8/8/2025)

Pharma MNCs in China H1/2025 – Mature Product... (8/8/2025)

Innovation through Talent: How Leadership Is E... (8/7/2025)

Big Pharma Provides Lifeline to Chinese Compan... (8/6/2025)

Novartis Heart Drug A China Case Study: How Dr... (8/6/2025)

What the Latest Volume-Based Procurement Chang... (8/1/2025)

China's Plan to Boost Drug Coverage by Commerc... (7/31/2025)

US Drug Supply Chain Exposure to China (Brooki... (7/29/2025)

Accelerating US Oncology Drug Development Usin... (7/23/2025)

PharmaDJ's China Biopharma Tracker – June 202... (7/22/2025)

Analysing Key Trends In China's Patent-linkage... (7/12/2025)

China's Rising Biotechnology Sector: Friend or... (7/10/2025)

Recent Executive Moves (8/8/2025) Jingxin Gains Exclusive China Rights to ... (8/8/2025) Wuxi Apptec Strengthens European Foothol... (8/8/2025) ExoNeuglia Raises Series A... (8/8/2025) Fujian Haixi Pharma Files for Hong Kong ... (8/8/2025) Hengrui Launches Phase 3 Trial of Trastu... (8/8/2025) Boan's Dulaglutide Biosimilar Secures NM... (8/8/2025) Triple Squeeze Threatens China's Global ... (8/8/2025) Shanghai Unveils 18 New Measures to Boos... (8/8/2025) Minghui Raises $131M to Accelerate Clini... (8/8/2025) Innogen Launches $87M Hong Kong IPO to F... (8/8/2025) AlphaGen Closes Series A Funding (8/8/2025) Dizal's Birelentinib Granted FDA Fast Tr... (8/8/2025) AsiFlyer Secures New Funding to Propel N... (8/8/2025) AstraZeneca Expands Use of Fasenra in Ch... (8/8/2025) Bio-Thera Launches Ambitious Triple-Immu... (8/8/2025) Minghui's MHB042C Earns Green Light for ... (8/8/2025) China Urges Price Discipline as Drugmake... (8/6/2025)

China's Innovative Drug Market Surpasses CNY 400 Billio... China's 'Silver Yuan' Set to Power US$134B Boom in Geri... China Hospitals Prioritize Local Innovation, Digital He... China's Pharma Market Faces Mixed Performance in Q1 202... China's Retail Pharmacy Market Hits CNY 941.1B in 2024 ...

AsiFlyer Secures New Funding to Propel Next‑Gen Botuli... AlphaGen Closes Series A Funding Innogen Launches $87M Hong Kong IPO to Fund Trials and ... Minghui Raises $131M to Accelerate Clinical and Commerc... Shanghai Unveils 18 New Measures to Boost Commercial He...

CDE Seeks Public Comments on Revised Technical Guidelin... CDE Solicits Comments on Guidelines for Developing Appr... CDE Releases Updated Roster of External Drug Review Exp... China Seeks Public Feedback on New Internet Drug and De... China Seeks Feedback on Draft Guidelines for Eosinophil...

China Launches 11th National VBP Round with New Flexibi... China Urges Price Discipline as Drugmakers Flood Latest... China Issues 2025 Code of Ethics for Medical Profession... China Officially Establishes New Launch Price Mechanism... China's Basic Medical Insurance Fund Reports Surplus in...

U.S. Closes Bribery Investigation into GE Healthcare's ... SAMR Orders Simcere to Reverse Unnotified Merger Over C... U.S. Lawmakers Raise Fresh Alarm Over GenScript's China... Record China Pharma Monopoly Fine Sends Strong Deterren... Conjupro Files USPTO Challenge on Ascletis' U.S. Patent...

India Moves to Set Minimum Import Prices to Protect Pha... China Struggles to Maintain Grip on India's Bulk Drug M... API China 2025 Ends with High Attendance and Global Ind... FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha...

Minghui's MHB042C Earns Green Light for Clinical Trials... Bio-Thera Launches Ambitious Triple-Immunotherapy Trial... AstraZeneca Expands Use of Fasenra in China Dizal's Birelentinib Granted FDA Fast Track for Treatme... Boan's Dulaglutide Biosimilar Secures NMPA Approval in ...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Recent Official and Executive Moves Recent Official and Executive Moves Recent Executive Moves Astellas Pharma Executive Sentenced to 3½ Years in Chi...

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...